Skip to main content

Advanced or Metastatic Pancreatic Adenocarcinoma S2433

Status: Open to Enrollment
Email us to enroll

Study details

View study details on clinicaltrials.gov.

Locations

  • Sutter Health System Wide

Clinical trial FAQs

Information for patients and study volunteers, including frequently asked questions.

Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Uma Suryadevara, M.D.
Uma Suryadevara, M.D.
Principal investigator
View profile

Related clinical trials

View all clinical trials
  • Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

    Status: Open to Enrollment

  • APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

    Status: Open to Enrollment

  • A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)

    Status: Open to Enrollment

  • Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Status: Open to Enrollment

  • A Randomized, Blinded, Placebo-controlled Trial of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Patients With Cancer Undergoing Chemotherapy

    Status: Open to Enrollment

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?